Purchase Order VA26217P7197
Award Date 9/18/17
Potential Completion Date 3/31/18
Potential Value $117K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Wayne, NJ, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award was made by the Department of Veterans Affairs (VA) to Bayer Healthcare Pharmaceuticals Inc., a subsidiary of the global pharmaceutical company Bayer AG. The $687,904.53 Firm Fixed Price Delivery Order is for the supply of radio pharmaceuticals and is part of a larger $840 million Multiple Award Federal Supply Schedule contract with the VA for Pharmaceuticals and Drugs. The contract has no set-aside designation, reflecting Bayer's status as a large, foreign-owned...
- This is a federal contract award to Bayer Healthcare Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company, by the U.S. Department of Veterans Affairs (VA). The contract, valued at $254,309.88, is for the delivery of Xofigo (radium Ra 223 dichloride) injection, a radiopharmaceutical used to treat prostate cancer. The contract is a delivery order under Bayer's existing VA Federal Supply Schedule contract for Pharmaceuticals and Drugs. The contract has no set-aside...
- This is a federal contract award from the Department of Veterans Affairs (VA) Veterans Health Administration to Bayer Healthcare Pharmaceuticals Inc. for the cancer treatment drug Xofigo. The contract is a Delivery Order awarded under Bayer's existing General Services Administration (GSA) Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs. The contract has a firm fixed price of $1,583,894.40 and a completion date of January 18, 2020. No small business set-aside was used. As a...
- This is a federal contract award to Bayer Healthcare Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company, for the delivery of XOFIGO, a specialized radiopharmaceutical product for the treatment of prostate cancer. The contract, valued at $90,214.74, was awarded by the Department of Veterans Affairs (VA) on October 23, 2019, with a completion date of May 31, 2020. The contract is a delivery order under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB),...
- This federal contract award, with an ID of V797P2202D|VA26116F0541, was issued to Bayer Healthcare Pharmaceuticals Inc., a foreign-owned, for-profit organization, by the Veterans Integrated Service Network 21 (VISN 21), a division of the U.S. Department of Veterans Affairs (VA). The award, which has a ceiling value of $158,394.50, is for the delivery of the pharmaceutical product XOFIGO, a radiopharmaceutical treatment for prostate cancer. The contract is a Firm Fixed Price Delivery Order,...
- This is a federal contract award to Bayer Healthcare Pharmaceuticals Inc., a foreign-owned, for-profit organization, by the Department of Veterans Affairs (VA) for the delivery of Xofigo Injection 6ML/VIAL. The contract has a ceiling value of $143,200.44 and is a Delivery Order issued under Bayer's $840 million VA Federal Supply Schedule contract for Pharmaceuticals and Drugs. There is no set-aside designation for this contract. The contract is for the delivery of the radiopharmaceutical product...
- This federal contract award is for the delivery of XOFIGO RA 223 injections to the Department of Veterans Affairs (VA) Veterans Health Administration. The prime contractor is Bayer Healthcare Pharmaceuticals Inc., a foreign-owned for-profit organization that specializes in the research, development, and marketing of pharmaceutical products. The contract was awarded on a firm fixed price basis under Bayer's General Services Administration (GSA) Federal Supply Schedule (FSS) 61-IB contract for...
- This federal contract award to Bayer Healthcare Pharmaceuticals Inc., a subsidiary of the global pharmaceutical company Bayer AG, is for the delivery of Xofigo (radium Ra 223 dichloride), a radiopharmaceutical used to treat prostate cancer. The $101,005.97 firm fixed-price delivery order was issued by the U.S. Department of Veterans Affairs (VA), under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. This multiple-award schedule contract has a potential value of $840...
- This is a federal contract award to Bayer Healthcare Pharmaceuticals Inc., a foreign-owned, for-profit organization, for the delivery of XOFIGO, a radiopharmaceutical product used in the treatment of prostate cancer. The contract, with a ceiling value of $82,156.02, was awarded by the Department of Veterans Affairs (VA) on October 24, 2016, and has an ultimate completion date of September 30, 2017. The contract is a delivery order under the VA's Pharmaceuticals and Drugs Federal Supply...
- This is a delivery order contract awarded by the Department of Veterans Affairs Veterans Health Administration to Bayer Healthcare Pharmaceuticals Inc., a subsidiary of Bayer AG, for the supply of the prostate cancer drug XOFIGO. The $1,134,223.67 contract is a firm fixed price agreement issued under Bayer's Federal Supply Schedule 61-IB contract for Pharmaceuticals and Drugs. The contract has a completion date of June 30, 2023 and does not utilize any small business set-aside. As a major...